In the Phase 1 trial of Adicet Bio's prula-cel, Grade 1 or 2 cytokine release syndrome occurred in 25% of patients, while Grade 3 or higher infections occurred in 8.3% of patients.

From the articleWedbush raises Adicet Bio stock price target on lupus trial data By Investing.comAlso in Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis, An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus